Rate of glycemic control and associated factors among type two diabetes mellitus patients in Ethiopia: A cross sectional study

Shambel Nigussie1*, Nigussie Birhan2, Firehiwot Amare1, Getnet Mengistu3, Fuad Adem1, Tadesse Melaku Abegaz4,5

1 Department of Clinical Pharmacy, School of Pharmacy, College of Health and Medical Science, Haramaya University, Harar, Ethiopia, 2 Department of Nursing, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia, 3 Pharmacology and Toxicology Unit, Pharmacy Department, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia, 4 Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia, 5 Clinical and Health Science, University of South Australia, Adelaide, Australia

* shambelpharm02@gmail.com

Abstract

Objective

To assess the rate of glycemic control and associated factors among type 2 diabetes mellitus patients at Dilchora Referral Hospital, Dire Dawa, Eastern Ethiopia.

Methods

A cross-sectional study was conducted from 13 May to 16 August 2019. Type 2 diabetic patients on follow up at Dilchora Referral Hospital who fulfilled the inclusion criteria of the study were included. Systematic random sampling was used to select study participants. Data was collected by a face-to-face interview and review of medical records. The primary outcome was the level of blood glucose during three consecutive visits. Poor glycemic control was defined as a blood sugar level of more than 154 mg/dL based on the average of measurements from three consecutive visits. Multivariate logistic regression analysis was used to identify determinants of glycemic control.

Result

A total of 394 participants responded to the interview and were included in the final analysis. The overall prevalence of poor glycemic control was 45.2% (95% CI: 40.6%-50.0%). Patients who were on oral anti-diabetic drug plus insulin had more than two times greater chance of poor glycemic control than patients on oral anti-diabetic drug alone: 2.177 (95% CI: 1.10–4.29). The odds of poor glycemic control in patients who did not understand the pharmacist’s instructions was two times higher than patients with good understanding of instructions 1.86 (95% CI: 1.10–3.13). Patients who had poor level of practice were found to have poor glycemic control: 1.69 (95% CI: 1.13–2.55).
Conclusion

The overall prevalence of poor glycemic control was high among type 2 diabetes patients. Oral anti-diabetic drugs in combination with insulin, lack of understanding of pharmacist’s advice, and poor practice of diabetic patients were significant factors of poor glycemic control. Pharmacists should reassure the understanding of patients before discharge during counseling. Optimization of the dose of antidiabetic medications and combination of oral hypoglycemic agents should be considered.

Introduction

Diabetes mellitus (DM) is a group of metabolic disorders which is characterized by the presence of high glucose level in the blood resulting from impairment in insulin secretion, insulin action, or both [1]. There are two broad types of DM, named type 1 which progresses as a result of autoimmunity against the insulin-producing beta cells and type 2 characterized by variable degrees of insulin resistance, impaired insulin secretion, and increased hepatic glucose production [2]. Globally, 451 million people were living with DM in 2017. This statistics was estimated to rise to 693 million by 2045 [3]. The global burden of disease data suggests DM to be responsible for 1.6 million deaths in 2016 [4, 5]. Despite the availability of a wide range of effective glucose-lowering therapies, approximately half of patients with type 2 diabetes mellitus (T2DM) in the world do not achieve glycemic targets. This increases the risk of diabetes-related complications and long-term health care costs [6, 7]. Poor blood glucose control causes about 7% of deaths among men aged 20–69 and 8% among female [8].

Maintaining blood sugar level within the range of ideal blood sugar control target is the most means of effective preventing complications associated with diabetes [9]. However, a ratio that is uncontrolled level of blood sugar for T2DM patients was very high. A multicenter study conducted in Eastern Europe, Asia, and Latin America showed that 96.4% of study participants had poor glycemic control [10]. Similarly, high proportions of T2DM patients with poor glycemic control ranging from 50% to 95.8% were reported in Brazil, south Indian, Karnataka, Uganda, Mthatha and Ghana [11–15]. In Ethiopia, hospital-based cross-sectional studies done at Gondar, Ambo, Jimma and Limmu indicated that 57.5%, 50%, 70.9%, 63.8% of participants had poor glycemic control, respectively [16–19]. The role of achieving the optimal blood glucose level in preventing the development and progression of complications is an established fact [9].

Even though studies established the influence of glycemic control on the progression of diabetic complications, small proportion of DM populations achieve the target glycemic level [11, 12, 20, 21]. Different factors have contributed to poor glycemic control including age, duration of the disease, type of treatment, patients’ perception of health, educational level, occupation, and medication adherence [22–25]. However, there is limited evidence on how these factors are associated with poor glycemic control in Ethiopia [26, 27]. Additionally, the previous studies did not assess the influence of knowledge, attitude, and practice of diabetic patients and their interaction with health professionals particularly with pharmacists [25, 28, 29]. The present study aimed to assess poor glycemic control and associated factors in Dilchora Referral Hospital, Eastern Ethiopia.
Methods and materials

Study design, study area and study period
A cross-sectional study was conducted in Dilchora Referral Hospital, Eastern Ethiopia, from 13 May to 16 August 2019. Dilchora Referral Hospital is the only referral hospital in Dire-Dawa city administration that provides service to approximately 11,229 inpatient and 118,886 outpatient attendees in 2016/2017 coming from a catchment population of 500,000.

Source and study population
The source population was all DM patients who had follow-up at outpatient chronic follow-up of Dilchora Referral Hospital. The study population was all T2DM patients who had follow-up at Dilchora Referral Hospital during the study period who fulfilled the inclusion criteria of the study.

Inclusion and exclusion criteria
T2DM patients who had follow-up at the clinic for at least one year with fasting blood glucose (FBG) measurements in the previous three consecutive months and above the age of 18 years were included. T2DM patients with mental disease, recurrent history of hypoglycemia and pregnant women were excluded.

Study variables
The dependent variable was the rate of glycemic control and independent variables were sex, age, residence, educational level, occupation, marital status, religion, ethnicity, rate of interaction with pharmacist, clarity of pharmacist advice, patient language preference during interaction with pharmacist, overall satisfaction with pharmaceutical service, cholesterol level, body mass index (BMI), diabetic complication, comorbidity, duration of DM, type of medications, duration of treatment, knowledge, attitude and practice of diabetic patients.

Sample size determination and sampling technique
The sample size was determined by using the formula of a single population proportion.

\[ n = \frac{Z^2 p(1-p)}{d^2} \]

where \( n \) is the sample size required; \( d \), margin of error of 5% (\( d = 0.05 \)); \( Z \), the degree of accuracy required at 95% confidence level = 1.96; and \( P \), prevalence rate of poor glycemic control. By reviewing different previous studies, we took a 50% prevalence rate of poor glycemic control which gave largest sample size and representativeness of the sample that finally ensures the generalization and precision of the findings [17].

Using the formula, the sample size was calculated as:

\[ n = \frac{1.96^2 \times 0.5 \times (1 - 0.5)}{0.05^2} = 384 \]

For possible nonresponse rate, 10% of the calculated sample was added to get a final sample size of 422 patients. Systematic random sampling technique was used to select study participants. The total numbers of T2DM patients who had follow-up at the diabetic clinic were 1308. The sampling interval was determined by dividing the number of patients on follow-up by the sample size of the study. The first patient was selected by lottery method from the list.
prepared based on their medical record number and then every three patients was recruited into the study.

Data collection methods

**Data collection tool.** A data abstraction format was used to record the necessary information from patients’ medical records and a structured questionnaire was used to interview patients. By using the data abstraction format information on body mass index, comorbid disease, diabetic complication, type of antidiabetic treatment, blood sugar level, systolic blood pressure, diastolic blood pressure, and cholesterol levels was retrieved from patient’s medical record. The structured questionnaire was prepared in English language and then translated to the local language (Amharic) to collect the data through face-to-face interviews. The questionnaire was prepared to collect information on residence, educational level, marital status, occupation, religion, ethnicity, family history of DM, duration of DM, participant interaction with the pharmacist, clarity of the pharmacist advice, patient language preference during interaction with the pharmacist, participants’ satisfaction with overall pharmaceutical service, and knowledge, attitude, and practice of DM patients. Knowledge of T2DM patients was assessed by using 12 general questions about diabetes. Each response was scored as “1” for the correct answer and “0” for an incorrect answer. Participants who correctly answered more than 50% of knowledge questions were considered as having adequate knowledge whereas those who scored less than 50% were considered as having inadequate knowledge. On the other hand, 8 attitude and 10 practice-related questions were included in the questionnaire. The responses to each question were scored as “1” for the correct answer and “0” for an incorrect answer. Participants who correctly answered more than 50% of attitude and practices assessing questions were considered as having good attitude and practices whereas those who scored less than 50% were considered as having poor attitude and practice, respectively.

**Data collection procedure.** The data was collected by three trained nurses who working in Dilchora Hospital. All the required laboratory values were taken from the patient medical record.

**Data quality control.** To ensure the quality of data, a pretest was done on 5% of the total sample. The pretest was conducted at chronic follow-up of Dilchora Referral Hospital on randomly selected T2DM patients to ensure the accuracy of the data abstraction format and the structured questionnaire. The findings of the pretest were not included in the final analysis. Any error found during the process of the pretest was corrected and modification was made into the final version of the data abstraction format and the structured questionnaire. After developing the questionnaire by reviewing different literature; submitted to the experts to comment the questionnaire and by incorporating their comment finalized our questionnaire to ensure the validity of data collection tool. The data collectors were trained before the process of data collection. Supervision and checking was made by the supervisor to ensure the completeness and consistency of the collected data. All collected data were examined for completeness and consistency during data management, storage, and analysis.

Data analysis and presentation

The collected data were entered into Epi Info 7 and analyzed using Statistical Package for Social Sciences (SPSS) version 20. Descriptive statistics like mean, frequency, and percentage were used to describe the characteristic of participants using table and text. multicollinearity among selected independent variables was checked through the variance inflation factor (VIF). Both binary and multivariate logistic regression analysis were done to identify determinants of poor glycemic control. In bivariate logistic regression analysis, variables with P-value
less than or equal to 0.2 were entered to multivariate logistic regression analysis to control for potential confounding variables that affect the poor glycemic level. Finally, statistically significant association of variables has been claimed based on the Adjusted Odds Ratio (AOR) with its 95%CI and P-value <0.05.

Ethical consideration
Ethical approval was obtained from the Ethical Research Committee of school of pharmacy, department of clinical pharmacy, University of Gondar. A permission letter was obtained from Dilchora Referral Hospital to undertake the study. Written informed consent was obtained from each participant. Confidentiality of the information was assured and the privacy of the participant’s medical record was maintained. To ensure confidentiality, names of patients and health care professionals were not recorded on the data collection tool.

Operational definitions

**Good blood glucose control.** When the average fasting blood sugar level on the previous three consecutive occasions of their visit to a hospital is less than 154mg/dl [30].

**Poor blood glucose control.** When the average fasting blood sugar level on the previous three consecutive occasions of their visit to the hospital is greater than or equal to 154mg/dl [30].

Results

Socio demographic and clinical characteristics of T2DM patients
A total of 422 patients were recruited to participate in this study. Of whom, 394 participants responded to the interview completely and included in the final analysis. The mean age of participants was 40.76 years with standard deviation (SD) of 12.79. More than half of the respondents 204 (51.8%) were females. Two hundred sixty (66%) participants lived in the urban areas. Most of the study participants 277 (70.3%) were married (Table 1). Half of the respondents 199 (50.5%) had no family history of DM. The overall mean of the duration of DM since diagnosis was 8.93 ±5.67 years, with a minimum of 1 years and maximum of 30 years. More than two third of respondents 277 (70.3%) had no comorbid disease. About 166 (42.1%) respondents had diabetic complications. Among the study participants, 28 (7.1%) and 46 (11.7%) respondents took atorvastatin and enalapril for the treatment of dyslipidemia and hypertension, respectively. The overall mean of the duration of DM treatment was 8.34 ±5.6 SD years, with a minimum of 1 year and a maximum of 30 years. Out of the total participants, 180 (45.7%) respondents were taking insulin alone (Table 2).

Interaction of T2DM patients with pharmacist
Around 171 (43.4%) respondents had a poor interaction with pharmacists. Nearly sixty percent of respondents 243 (61.7%) preferred the Amharic language to communicate with a pharmacist. More than half of the study participants 233 (59.1%) understood the pharmacist’s advice regarding their medication. More than fifty percent of respondents 208 (52.8%) were not satisfied with the overall pharmaceutical service obtained from pharmacists (Table 3).

Knowledge, attitude and practice of T2DM patients
More than half of the respondents 222 (56.3%) had inadequate knowledge about T2DM. Around 288 (73.1%) respondents had a good attitude towards T2DM. Less than half of the respondents 190 (48.2%) had a poor practice of DM (Table 4).
Prevalence of poor glycemic control in T2DM patients

The overall prevalence of poor glycemic control was 45.2% (95%CI: 40.6–50.0). The overall mean (SD) fasting blood sugar was 154.57mg/dl ± 36.33 SD. Around 100 (56.2%) females, 119 (66.85) respondents who live in urban and a quarter of subjects in primary 43 (24.15%) and secondary school 46 (25.8%) had poor glycemic control. The majority of respondents who had poor glycemic control were married 118 (66.3%). Approximately fifty percent of participants 92 (51.7%) who had no family history of DM had poor glycemic control. Ninety-nine (55.6%) subjects had poor glycemic control without DM complications. Poor glycemic control was predominant in the participants 126 (70.8%) who had no comorbid disease. Around 79 (44.4%) respondents who had poor rates of interaction with a pharmacist had poor glycemic control. Near to sixty percent of participants 113 (63.5%) who understood the advice of pharmacist about their drugs had poor glycemic control. More than fifty percent 103 (57.9%) of participants with inadequate knowledge had poor glycemic control. The prevalence of poor glycemic control was found to be 132 (74.2%) and 98 (55.1%) in patients with good attitude and practice, respectively. The prevalence of poor glycemic control among participants who had been taking

Table 1. Socio demographic characteristics of T2DM patients who were attending Dilchora Referral Hospital, September 2019.

| Characteristics       | Frequency (%) | Glycemic level |
|-----------------------|---------------|----------------|
|                       |               | Good (%)       | Poor (%)       |
| Sex                   |               |                |                |
| Female                | 204 (51.8)    | 104 (51)       | 100 (49)       |
| Male                  | 190 (48.2)    | 112 (58.9)     | 78 (41.1)      |
| Age (years)           |               |                |                |
| 18–39                 | 175 (44.4)    | 94 (53.7)      | 81 (46.3)      |
| 40–59                 | 184 (46.7)    | 101 (54.9)     | 83 (45.1)      |
| ≥ 60                  | 35 (8.9)      | 21 (60)        | 14 (40)        |
| Current residence     |               |                |                |
| Urban                 | 260 (66)      | 141 (54.2)     | 119 (45.8)     |
| Rural                 | 134 (34)      | 75 (56)        | 59 (44)        |
| Educational level     |               |                |                |
| Unable to read and write | 79 (20.1)   | 52 (65.8)      | 27 (34.2)      |
| Able to read and write | 48 (12.2)    | 23 (47.9)      | 25 (52.1)      |
| Primary school        | 86 (21.8)     | 43 (50)        | 43 (50)        |
| Secondary school      | 104 (26.4)    | 58 (55.8)      | 46 (44.2)      |
| Tertiary and above    | 77 (19.5)     | 40 (51.9)      | 37 (48.1)      |
| Marital status        |               |                |                |
| Single                | 81 (20.6)     | 39 (48.1)      | 42 (51.9)      |
| Married               | 277 (70.3)    | 159 (57.4)     | 118 (42.6)     |
| Widowed               | 6 (1.5)       | 3 (50)         | 3 (50)         |
| Divorced              | 30 (7.6)      | 15 (50)        | 15 (50)        |
| Occupation            |               |                |                |
| Student               | 69 (17.5)     | 33 (47.8)      | 36 (52.2)      |
| Employed              | 131 (33.2)    | 80 (61.1)      | 51 (38.9)      |
| Housewife             | 64 (16.2)     | 33 (51.6)      | 31 (48.1)      |
| Merchant              | 52 (13.2)     | 30 (57.7)      | 22 (42.3)      |
| Daily laborer         | 78 (19.8)     | 40 (51.3)      | 38 (48.7)      |
| Religion              |               |                |                |
| Orthodox              | 180 (45.7)    | 97 (53.9)      | 83 (46.1)      |
| Protestant            | 70 (17.8)     | 39 (55.7)      | 31 (44.3)      |
| Muslim                | 144 (36.5)    | 80 (55.6)      | 64 (44.4)      |
| Ethnicity             |               |                |                |
| Oromo                 | 148 (37.6)    | 76 (51.4)      | 72 (48.6)      |
| Amhara                | 104 (26.4)    | 57 (54.8)      | 47 (45.2)      |
| Somali                | 50 (12.7)     | 30 (60)        | 20 (40)        |
| Tigrae                | 54 (13.7)     | 32 (59.3)      | 22 (40.7)      |
| Woleyta               | 38 (9.6)      | 21 (55.3)      | 17 (44.7)      |

https://doi.org/10.1371/journal.pone.0251506.t001
Table 2. Clinical characteristics of T2DM patients who were attending Dilchora Hospital, September 2019.

| Characteristics             | Frequency (%) | Glycemic level |
|-----------------------------|---------------|----------------|
|                             |               | Good (%) | Poor (%) |
| Family history of DM        |               |          |          |
| Yes                         | 195(49.5)     | 109(55.9) | 86(44.1) |
| No                          | 199(50.5)     | 107(53.8) | 92(46.2) |
| Duration of DM              |               |          |          |
| < 7 years                   | 162(41.1)     | 91(56.2)  | 71(43.8) |
| ≥ 7 years                   | 232(58.9)     | 125(53.9) | 107(47.1) |
| Comorbid disease            |               |          |          |
| Yes                         | 117(29.7)     | 65(55.6)  | 52(44.4) |
| No                          | 277(70.3)     | 151(54.5) | 126(45.5) |
| Diabetic complication       |               |          |          |
| Yes                         | 166(42.1)     | 87(52.4)  | 79(47.6) |
| No                          | 228(57.9)     | 129(56.6) | 99(43.4) |
| Drug given for dyslipidemia |               |          |          |
| Atorvastatin                | 28(7.1)       | 16(57.1)  | 12(42.9) |
| Simvastatin                 | 18(4.6)       | 10(55.6)  | 8(44.4)  |
| Drug given for hypertension |               |          |          |
| Amlodipine                  | 11(2.8)       | 11(100)   | 0(0.0)   |
| Enalapril                   | 46(11.7)      | 23(50)    | 23(50)   |
| Enalapril + Amlodipine      | 8(2)          | 5(62.5)   | 3(37.5)  |
| Enalapril + HCT             | 11(2.8)       | 3(27.3)   | 8(72.7)  |
| Enalapril + HCT + Amlodipine| 1(0.3)        | 1(100)    | 0(0.0)   |
| Enalapril + Nifedipine      | 3(0.8)        | 2(66.7)   | 1(33.3)  |
| HCT + Amlodipine            | 4(1)          | 2(50)     | 2(50)    |
| HCT + Nifedipine            | 1(0.3)        | 1(100)    | 0(0.0)   |
| HCT                         | 4(1)          | 3(75)     | 1(25)    |
| Nifedipine                  | 4(1)          | 2(50)     | 2(50)    |
| Duration of DM treatment    |               |          |          |
| < 7 years                   | 207(52.5)     | 117(56.5) | 90(43.5) |
| ≥ 7 years                   | 187(47.5)     | 99(52.9)  | 88(47.1) |
| Total number of anti-diabetic drugs | |          |          |
| One drug                    | 298(75.6)     | 170(57)   | 128(43)  |
| Two drugs                   | 88(22.5)      | 41(46.6)  | 47(53.4) |
| Three drugs                 | 8(2)          | 5(62.5)   | 3(37.5)  |
| Types of treatment          |               |          |          |
| Oral anti diabetic drug     | 164(41.6)     | 92(56.1)  | 72(43.9) |
| Insulin                     | 180(45.7)     | 105(58.3) | 75(41.7) |
| Oral anti diabetics + insulin | 50(12.7)     | 19(38)    | 31(62)   |

https://doi.org/10.1371/journal.pone.0251506.t002

Table 3. Interaction of T2DM patients who were attending Dilchora Referral Hospital with Pharmacist, September 2019.

| Characteristics                        | Frequency (%) | Glycemic level |
|----------------------------------------|---------------|----------------|
|                                        |               | Good (%) | Poor (%) |
| rate of interaction with the pharmacist|               |          |          |
| Good                                   | 141(35.8)     | 80(56.7) | 61(43.3) |
| Moderate                               | 82(20.8)      | 44(53.7) | 38(46.3) |
| Poor                                   | 171(43.4)     | 92(53.8) | 79(46.2) |
| Patient language preference to communicate with pharmacist | |          |          |
| Amharic                                | 243(61.7)     | 131(53.9) | 112(46.1) |
| Afan oromo                             | 70(17.8)      | 42(60)   | 28(40)   |
| Adarigna                               | 3(0.8)        | 3(100)   | 0(0.0)   |
| Somali                                 | 33(8.4)       | 18(54.5) | 15(45.5) |
| Woleytgna                              | 45(11.4)      | 22(48.9) | 23(51.1) |
| clarity of the pharmacist advice about their drug | |          |          |
| clear                                  | 233(59.1)     | 120(51.5) | 113(48.5) |
| not clear                              | 161(40.9)     | 96(39.6)  | 65(40.4) |
| Satisfied with overall pharmaceutical service get from pharmacists | |          |          |
| Yes                                    | 186(47.2)     | 102(54.8) | 84(45.2) |
| No                                     | 208(52.8)     | 114(54.8) | 94(45.2) |

https://doi.org/10.1371/journal.pone.0251506.t003
oral anti-diabetic drugs was 72(40.4%) while among those who had been taking insulin was 75 (42.1%) (Tables 1–4).

Factors associated with poor glycemic control among T2DM patients

In multivariable logistic regression analysis, the variables with significant effects on poor glycemic control include taking an oral anti-diabetic drug with insulin, level of understanding of pharmacist’ advice regarding drugs and poor practice of diabetic patients. Participants who were on oral anti-diabetic drug plus insulin therapy had nearly two times the likelihood of poor glycemic control than those who were on oral anti-diabetic drug alone: adjusted odds ratio (AOR) = 2.177; 95% confidence interval (CI): [1.104, 4.294; p = 0.025]. The odd of poor glycemic control in participants who were not able to understand the pharmacist’s advice regarding their drug was approximately two times higher than in those who understood the pharmacist’s advice: AOR = 1.857; 95%CI: [1.100, 3.132; p = 0.020]. patients with a poor level of practice were 1.5 times more likely to have poor glycemic control than those who had a good level of practice: AOR = 1.693; 95% CI: [1.126, 2.545; p = 0.011] (Table 5).

Discussion

This study was carried out to assess poor glycemic control and its determinants among T2DM outpatients in one of the major hospitals in Eastern Ethiopia. Poor glycemic control was observed in 45.2% of participants (95%CI: 40.6–50.0). Being on oral anti-diabetic drug plus insulin therapy, unable to understood pharmacist’s advice about their drug and having a poor practice of DM were significantly associated with poor glycemic control.
In the present study, 45.2% of the participants had poor glycemic control. The proportion of poor glycemic control was comparable to the results reported in Ambo, Brazil, Iran, and Jordan [11, 17, 31, 32]. In other studies, carried out in Riyadh (67.7%), Al-Hasa (67.9%), Jazan (74%), Oman (65.0%), United Arab Emirates (69%), Kuwait (78.8%) and Rawalpindi (76%) [33–39], poor glycemic control was higher unlike the current study. This discrepancy may have happened due to the difference in socioeconomic status, culture, environmental factors, and lifestyle, which predispose individuals to different risk factors of poor glycemic control.

In this study, a high-level prevalence of poor glycemic control was presented among study participants who were on insulin treatment (40%) and Oral anti–diabetic drugs (42.1%). The results were lined with other studies [20, 40]. Starting insulin therapy for T2DM patients often showed blood glucose level is not well controlled [41, 42].

In the current study, a higher proportion of poor glycemic control was reported in study participants who live with DM for a long duration of period since diagnosis (60.1%). But a study conducted at the University of Gondar Hospital revealed that a high proportion of poor glycemic control was observed in those patients who live with DM for less than seven years (68.5%) [43]. It is understood that progressive impairment of insulin secretion through time because of β cell failure could lead to poor glycemic control [44].

This study revealed that the combination of an oral anti-diabetic drug plus insulin therapy is significantly associated with a poor glycemic control. The finding is in line with prior research studies [20, 45] and contradicts the study conducted in India which reported no significant association between oral anti-diabetic drug plus insulin therapy with poor glycemic control [46].

In the current study, participants who had a poor level of practice were found to have poor glycemic control than those who had a good level of practice. Because of the progressive nature of T2DM, treatment with drugs alone is not adequate to maintain euglycemia over time. Rather, after the medication is initiated, diabetic patients are encouraged to include lifestyle management including avoiding refined sugars as in soft drinks, increase in the amount of fiber, avoiding cigarettes, other tobacco products and alcohol and engaging in regular aerobic activity [1, 47]. The odd of poor glycemic control in study participants who were not able to understand the pharmacist’s advice was higher than in those who understand the pharmacist advice. An interventional study conducted in Nadu and Iraq revealed a statistically significant reduction in the mean blood glucose level among patients advised by pharmacists appropriately [48, 49]. Patient-pharmacist interaction might improve patient’s adherence to medication and other instructions which in turn help to achieve adequate control of DM. In this study factors associated with poor glycemic control were assessed using across-sectional design, which might not show causal relationships with potential risk factors.

**Conclusion and recommendation**

This study revealed that the overall prevalence of poor glycemic control was high in Dilchora Referral Hospital. Patients on a combination of hypoglycemic drugs and insulin, a poor understanding of pharmacist’s advice regarding medications and having poor practice of T2DM were risk factors for poor glycemic control. Health professionals working in the hospital should provide better patient advice about medications and should design treatment strategies for T2DM. A cohort study is recommended to infer substantial evidence of causality. In addition, the level of glycemic control should be determined by using the HbA1c test which is a good predictor of glycemic control over a long period of time.
Supporting information

S1 File.
(DOCX)

S2 File.
(DOCX)

Acknowledgments

The authors would like to express gratitude to the participants of the study for their time and the information they provided. We would also like to acknowledge the administrators of Dilchora Referral Hospital and the data collectors for their cooperation. Lastly, we would like to thank our colleague for reviewing grammar.

Author Contributions

Conceptualization: Shambel Nigussie, Nigussie Birhan, Firehiwot Amare, Getnet Mengistu, Fuad Adem, Tadesse Melaku Abegaz.

Data curation: Tadesse Melaku Abegaz.

Formal analysis: Shambel Nigussie, Nigussie Birhan, Firehiwot Amare, Getnet Mengistu, Fuad Adem, Tadesse Melaku Abegaz.

Methodology: Shambel Nigussie, Nigussie Birhan, Firehiwot Amare, Getnet Mengistu, Fuad Adem, Tadesse Melaku Abegaz.

Supervision: Shambel Nigussie.

Validation: Tadesse Melaku Abegaz.

Visualization: Tadesse Melaku Abegaz.

Writing – original draft: Shambel Nigussie, Nigussie Birhan, Firehiwot Amare, Getnet Mengistu, Fuad Adem, Tadesse Melaku Abegaz.

Writing – review & editing: Shambel Nigussie, Nigussie Birhan, Firehiwot Amare, Getnet Mengistu, Fuad Adem, Tadesse Melaku Abegaz.

References

1. Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2019. Diabetes Care. 2019; 42(Supplement 1):S13–S28. https://doi.org/10.2337/dc19-S002 PMID: 30559228

2. Mary Anne codakimble YYY, Brian K. Aldredge, Robin L. Corelli, B. Joseph Guglielmo, Wayne A. kradjan and Bradley R. williams. Applied Therapeutics clinical use of drugs.10th edition.

3. Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes research and clinical practice. 2018; 138:271–81. https://doi.org/10.1016/j.diabres.2018.02.023 PMID: 29496507

4. Organization WH. updates fact sheet on Top 10 causes of Death. 2017.

5. Organization WH. Global data on visual impairments 2010. Geneva: World Health Organization Organization. 2012.

6. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? Diabetes care. 2008; 31(1):81–6. https://doi.org/10.2337/dc07-1572 PMID: 17934153

7. Braga MF, Casanova A, Teoh H, Dawson KG, Gerstein HC, Fitchett DH, et al. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Canadian Journal of Cardiology. 2010; 26(6):297–302. https://doi.org/10.1016/s0828-282x(10)70393-7 PMID: 20548975
8. Roglic G. WHO Global report on diabetes: A summary. International Journal of Noncommunicable Diseases. 2016; 1(1):3.

9. Reaven PD, Emanuele NV, Witala WL, Bahn GD, Reda DJ, McCarron M, et al. Intensive glucose control in patients with type 2 diabetes—15-year follow-up. New England Journal of Medicine. 2019; 380(23):2215–24. https://doi.org/10.1056/NEJMoa1806802 PMID: 31167051

10. Chan JC, Gagliardino JJ, Baik SH, Chantelot J-M, Ferreira SR, Hancu N, et al. Multifaceted determinants for achieving glycemic control: the International Diabetes Management Practice Study (IDMPS). Diabetes care. 2009; 32(2):227–33. https://doi.org/10.2337/dc08-0435 PMID: 19033410

11. Lozovey NR, Lamback EB, Mota RB, Caarls MB, Neto LV. Glycemic control rate in type 2 diabetes mellitus patients at a public referral hospital in Rio de Janeiro, Brazil: demographic and clinical factors. Journal of Endocrinology and Metabolism. 2017; 7(2):61–7.

12. VENKATARAMAN RAJESH M JM, THOMAS LINU & JAMES MATHEW. IMPACT OF DEMOGRAPHIC VARIABLES ON BLOOD PRESSURE AND GLYCEMIC CONTROL. ASIAN Journal of Pharmaceutical and Clinical Research. 2018; 11 (10):179–81.

13. De P, Banu S, Muthukumar D. Predictors of poor glycemic control in type 2 diabetic patients in South Indian population. International Journal of Research in Medical Sciences. 2018; 6:545.

14. Fiagbe J, B S, Opong J, Takramah W, Axame W, Owusu R, et al. Prevalence of controlled and uncontrolled diabetes mellitus and associated factors of controlled diabetes among diabetic adults in the hohoe municipality of Ghana. Diabetes Management. 2017; 7(5):343–54.

15. Adeniyi Odalele Vincent Y P L M B, Ter Goon Daniel & Ajayi Anthony Idowu. Cross-sectional study of patients with type 2 diabetes in OR Tambo district, South Africa. BMJ open. 2016; 6(7).

16. Woldu M, Wami C, Lenjisa J, Tegegne G, Tesafye G, Dinsa H. Factors associated with poor glycemic control among patients with type 2 diabetes mellitus in Ambo Hospital, Ambo; Ethiopia. Endocrinol Metab Synd. 2014; 3(143):2161–1017.

17. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC research notes. 2016; 9(1):78. https://doi.org/10.1186/s13104-016-1896-7 PMID: 26861243

18. Kassahun Tefera E T G H. Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC research notes. 2016; 9(1):78. https://doi.org/10.1186/s13104-016-1896-7 PMID: 26861243

19. Bayisa B B M. Glycemic Control and Associated Factors among Type II Diabetic Patients on Chronic Follow up at Southwest Ethiopia. 2017. 6(3).

20. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. Journal of Diabetes and its Complications. 2010; 24(2):84–9. https://doi.org/10.1016/j.jdiacomp.2008.12.008 PMID: 19282203

21. Al-Nuaim AR, Mirdad S, Al-Rubeaan K, Al-Mazrou Y, Al-Attas O, Al-Daghari N. Pattern and factors associated with glycemic control of Saudi diabetic patients. Ann Saudi Med. 1998; 18(2):109–12. https://doi.org/10.5144/0256-4947.1998.109 PMID: 17341938

22. Samancio glu S, Surucu HA, Donmez RO, Cevik AB. Factors Affecting Glycemic Control in Type 2 Diabetics and Diabetics’ Attitude towards the Disease. International Journal of Caring Sciences. 2017; 10(2):889.

23. Al Mansari A, Obeid Y, Islam N, Fariduddin M, Hassoun A, Djaballah K, et al. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in patients with type 2 diabetes in real clinical practice. BMJ Open Diabetes Research and Care. 2018; 6(1):e000519. https://doi.org/10.1136/bmjdr-2018-000519 PMID: 30023075

24. Reipath DD, Soyiri I, Jahan NK, Mohan D, Ahmad B, Ahmad MP, et al. Poor glycaemic control and its metabolic and demographic risk factors in a Malaysian community-based study. International journal of public health. 2018; 63(2):193–202. https://doi.org/10.1007/s00038-017-1072-4 PMID: 29372287

25. Kassahun T, Eshete T, Gesezew H. Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC research notes. 2016; 9(1):78. https://doi.org/10.1186/s13104-016-1896-7 PMID: 26861243

26. Guo X, Weng J, Lu J, Yang W, Jia W, Zou D, et al. Determinants of poor glycemic control in Chinese men with type 2 diabetes: a cross-sectional survey of 15,427 men in 77 tertiary hospitals in China. International Journal of Diabetes in Developing Countries. 2015; 35(4):488–92.

27. Kamnabwawa AR, Charles E. Predictors of poor glycemic control in type 2 diabetic patients attending public hospitals in Dar es Salaam. Drug, healthcare and patient safety. 2014; 6:155. https://doi.org/10.2147/DHPS.S68786 PMID: 25368533
28. Fiagbe J, Bosoka S, Opon J, Takramah W, Axame W, Owusu R, et al. Prevalence of controlled and uncontrolled diabetes mellitus and associated factors of controlled diabetes among diabetic adults in the hohoe municipality of Ghana. Diabetes Management. 2017; 7(5):343–54.

29. Pablo C, Mohammadnezhad M, Wilson D, Khan S. Socio-demographic Determinants of Poor Glycemic Control among Type 2 Diabetes Mellitus (T2DM) Patients Attending Clinics at the Three Selected Health Facilities in Suva, Fiji in 2011–2016. J Diabetic Complications Med. 2018; 3(120):2.

30. Care D. Standards of Medical Care in Diabetes 2019. Diabetes Care. 2019; 42:S81.

31. Mohammad S, Karim NA, Talib RA, Amani R. Knowledge, attitude and practices on diabetes among type 2 diabetic patients in Iran: a cross-sectional study. Science. 2015; 3(4):520–4.

32. Lumanlani DB, Quiaoit-Alagarbes S. Knowledge, attitudes and practices and its association with glycemic control among type 2 diabetes mellitus patients in a tertiary hospital. Diabetes Research and Clinical Practice. 2016; 120:S175.

33. Rasheed M, Islam N, Mahjabeen W. Factors Associated with Uncontrolled Type 2 Diabetes Mellitus. Journal of Islamabad Medical & Dental College (JIMDC). 2015; 4(2):68–71.

34. Badedi M, Solan Y, Darraj H, Sabai A, Mahfouz M, Alamodi S, et al. Factors associated with long-term control of type 2 diabetes mellitus. Journal of diabetes research. 2016; 2016. https://doi.org/10.1155/2016/2109542 PMID: 28090538

35. Al-Rasheed AAS. The role of educational level in glycemic control among patients with type II diabetes mellitus. International journal of health sciences. 2014; 8(2):177. https://doi.org/10.12816/0006084 PMID: 25246885

36. Khan AR, A-A Lateef ZN, Al Aithan MA, Bu-Khamseen MA, Al Ibrahim I, Khan SA. Factors contributing to non-compliance among diabetics attending primary health centers in the Al Hasa district of Saudi Arabia. Journal of Family and Community Medicine. 2012; 19(1):26. https://doi.org/10.4103/2230-8229.94008 PMID: 22518355

37. Al-Rasheed AA. Glycemic control among patients with type 2 diabetes mellitus in countries of Arabic Gulf. International journal of health sciences. 2015; 9(3):345. PMID: 26609299

38. Al-Kaabi J, Al-Maskari F, Saadi H, Afandi B, Parkar H, Nagelkerke N. Assessment of dietary practice among diabetic patients in the United Arab Emirates. The review of diabetic studies: RDS. 2008; 5(2):110. https://doi.org/10.1900/RDS.2008.5.110 PMID: 18795213

39. Al-Ibrahim AAH. Factors associated with compliance to diabetes self-care behaviors and glycemic control among Kuwait people with type 2 diabetes 2012.

40. Oluma A, A M, Mosisa G, Etafa W. Magnitude and predictors of poor glycemic control among patients with diabetes attending public hospitals of Western Ethiopia. PloS one. 2021; 16(2). https://doi.org/10.1371/journal.pone.0247634 PMID: 33630936

41. Association AD. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes:standards of medical care in diabetes. Diabetes Care. 2021; 44. https://doi.org/10.2337/dc21-S009 PMID: 33298420

42. Peyrot M, Barnett A, Meneghini L, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic Medicine. 2012; 29(5):682–9. https://doi.org/10.1111/j.1464-5491.2012.03605.x PMID: 22313123

43. Fasil alebachew Ba B A M. glycemic control and diabetes complications among diabetes mellitus patients attending at University of gonder hospital, northwest ethiopia. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2018. 2018; 2. https://doi.org/10.2147/DMSO.S185614 PMID: 30613158

44. Mohammad HA F H, Metwalley KA, Monazea EM, Abd ElHafeez HA. Predictors of glycemic control in children with Type 1 diabetes mellitus in Assiut-Egypt. Indian J Endocrinol Metab. 2012; 16(5). PMID: 23087867

45. Goudswaard AN, Stolk RP, Zuilhoff P, Rutten GE. Patient characteristics do not predict poor glycemic control in type 2 diabetes patients treated in primary care. European journal of epidemiology. 2004; 19(6):541–5. https://doi.org/10.1023/b:eijp.0000032351.42772.e7 PMID: 15330126

46. Kakade Ashutosh A M IR R S. Assessment of factors associated with poor glycemic control among patients with Type II Diabetes mellitus. Integrative Obesity and Diabetes. 2018; 4(3):1–6.

47. Food E. Medicine and Healthcare Administration and Control Authority. Continuing Professional Development (CPD) Guideline for Health Professionals in Ethiopia Addis Ababa: FMoH. 2013.

48. Venkatesan R, Devi AM, Parasuraman S, Sriram S. Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes. Perspectives in clinical research. 2012; 3(1):26. https://doi.org/10.4103/2229-3485.92304 PMID: 22347699

49. Obied KA M TO. role of the pharmaceutical care in the management of patient with type 2 diabetes mellitus international journal of pharmaceutical science. 2013, 4(4).